CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present new functional and quality-of-life data in children with hypophosphatasia (HPP) treated with Strensiq® (asfotase alfa) for at least five years, as well as new data on the biochemical and physical function outcomes in juveniles and adults with HPP treated with Strensiq for up to four years. Researchers will also present new safety and efficacy data in infants with HPP treated with Strensiq for up to three and a half years. Data will be presented in two oral sessions and one poster presentation at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO), being held April 1-4, 2016, in Boston.
